Bitcoin pioneer Charlie Shrem peels back the layers on the lives and backgrounds of the world's most impactful innovators. Centering around intimate narratives, Shrem uncovers a detailed, previously unspoken story of the genesis and evolution of bitcoin, cryptocurrency, artificial intelligence, and the web3 movements. Join Shrem as he journeys through the uncharted territories of tech revolutions, revealing the human side of the stories that shaped the digital world we live in today.
…
continue reading
Content provided by jruss88 and Vox Markets Podcast. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by jruss88 and Vox Markets Podcast or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
1899: Hvivo Q&A: “this contract is important as it opens up new markets”
MP3•Episode home
Manage episode 421746093 series 2936804
Content provided by jruss88 and Vox Markets Podcast. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by jruss88 and Vox Markets Podcast or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Watch on YouTube
Vox Markets speaks to Mo Khan, CEO of clinical research specialist Hvivo, about a new $2.5 million contract for an Omicron variant study to determine the virus dose needed to infect vaccinated individuals. This study will facilitate future human challenge trials to test vaccines and antivirals, with significant developments expected in 2025, expanding H Vivo’s market opportunities.
Vox Markets speaks to Mo Khan, CEO of clinical research specialist Hvivo, about a new $2.5 million contract for an Omicron variant study to determine the virus dose needed to infect vaccinated individuals. This study will facilitate future human challenge trials to test vaccines and antivirals, with significant developments expected in 2025, expanding H Vivo’s market opportunities.
1961 episodes
MP3•Episode home
Manage episode 421746093 series 2936804
Content provided by jruss88 and Vox Markets Podcast. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by jruss88 and Vox Markets Podcast or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Watch on YouTube
Vox Markets speaks to Mo Khan, CEO of clinical research specialist Hvivo, about a new $2.5 million contract for an Omicron variant study to determine the virus dose needed to infect vaccinated individuals. This study will facilitate future human challenge trials to test vaccines and antivirals, with significant developments expected in 2025, expanding H Vivo’s market opportunities.
Vox Markets speaks to Mo Khan, CEO of clinical research specialist Hvivo, about a new $2.5 million contract for an Omicron variant study to determine the virus dose needed to infect vaccinated individuals. This study will facilitate future human challenge trials to test vaccines and antivirals, with significant developments expected in 2025, expanding H Vivo’s market opportunities.
1961 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.